Top

Published in:

01-03-2016

Genetic traits for hematogeneous tumor cell dissemination in cancer patients

Authors: Simon A. Joosse, Klaus Pantel

Published in: Cancer and Metastasis Reviews | Issue 1/2016

Abstract

Metastatic relapse in patients with solid tumors is the consequence of cancer cells that disseminated to distant sites, adapted to the new microenvironment, and escaped systemic adjuvant therapy. There is increasing evidence that hematogeneous dissemination starts at an early stage of cancer progression with single tumor cells or cell clusters leaving the primary site and entering the blood circulation. These circulating tumor cells (CTCs) can extravasate into secondary tissues where they become disseminated tumor cells (DTCs). Patients might relapse years after initial resection of the primary tumor when DTCs become overt metastases. Current diagnostic strategies for stratification of therapies against metastatic cells focus on the primary tumor tissue. This approach is based on the availability of stored primary tumors obtained at primary surgery, but it ignores that the DTCs might have evolved over years, which can affect the antimetastatic drug response. However, taking biopsies from metastatic tissues is an invasive procedure, and multiple metastases located at different sites in an individual patient show marked genomic heterogeneity. Thus, capturing CTCs from the peripheral blood as a “liquid biopsy” has obvious advantages in particular when repeated sampling is required for monitoring therapies in cancer patients. However, the biology behind tumor cell dissemination and its contribution to metastatic progression in cancer patients is still subject to controversial discussions. This manuscript reviews current theories on the genetic traits behind the spread of CTCs and progression of DTCs into overt metastases.

Muller, V., Alix-Panabieres, C., & Pantel, K. (2010). Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies. European Journal of Cancer, 46(7), 1189–1197. doi:10.1016/j.ejca.2010.02.038.CrossRefPubMed

Joosse, S.A., Gorges, T.M., & Pantel, K. (2014). Biology, detection, and clinical implications of circulating tumor cells. EMBO Molecular Medicine, 7(1),1–11. doi: 10.15252/emmm.201303698.

Joosse, S. A., & Pantel, K. (2013). Biologic challenges in the detection of circulating tumor cells. Cancer Research, 73(1), 8–11. doi:10.1158/0008-5472.CAN-12-3422.CrossRefPubMed

Joosse, S. A., Hannemann, J., Spotter, J., Bauche, A., Andreas, A., Muller, V., et al. (2012). Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 18(4), 993–1003. doi:10.1158/1078-0432.CCR-11-2100.CrossRefPubMed

Riethdorf, S., Fritsche, H., Muller, V., Rau, T., Schindlbeck, C., Rack, B., et al. (2007). Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 13(3), 920–928. doi:10.1158/1078-0432.CCR-06-1695.CrossRefPubMed

Zhang, L., Riethdorf, S., Wu, G., Wang, T., Yang, K., Peng, G., et al. (2012). Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clinical Cancer Research An Official Journal Of the American Association for Cancer Research, 18(20), 5701–5710. doi:10.1158/1078-0432.CCR-12-1587.CrossRefPubMed

Babayan, A., Hannemann, J., Spotter, J., Muller, V., Pantel, K., & Joosse, S. A. (2013). Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. PLoS ONE, 8(9), e75038. doi:10.1371/journal.pone.0075038.CrossRefPubMedPubMedCentral

Schramm, A., Friedl, T. W., Schochter, F., Scholz, C., de Gregorio, N., Huober, J., et al. (2015). Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program. Archives of Gynecology and Obstetrics. doi:10.1007/s00404-015-3879-7.

Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., et al. (2014). AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. The New England Journal of Medicine, 371(11), 1028–1038. doi:10.1056/NEJMoa1315815.CrossRefPubMedPubMedCentral

10.

Thiery, J. P., Acloque, H., Huang, R. Y., & Nieto, M. A. (2009). Epithelial-mesenchymal transitions in development and disease. Cell, 139(5), 871–890. doi:10.1016/j.cell.2009.11.007.CrossRefPubMed

11.

Lange, T., Samatov, T. R., Tonevitsky, A. G., & Schumacher, U. (2014). Importance of altered glycoprotein-bound N- and O-glycans for epithelial-to-mesenchymal transition and adhesion of cancer cells. Carbohydrate Research, 389, 39–45. doi:10.1016/j.carres.2014.01.010.CrossRefPubMed

12.

Dancey, J. E., Bedard, P. L., Onetto, N., & Hudson, T. J. (2012). The genetic basis for cancer treatment decisions. Cell, 148(3), 409–420. doi:10.1016/j.cell.2012.01.014.CrossRefPubMed

13.

Dienstmann, R., Rodon, J., & Tabernero, J. (2013). Biomarker-driven patient selection for early clinical trials. Current Opinion in Oncology, 25(3), 305–312. doi:10.1097/CCO.0b013e32835ff3cb.PubMed

14.

Alix-Panabieres, C., & Pantel, K. (2014). Challenges in circulating tumour cell research. Nature Reviews Cancer, 14(9), 623–631. doi:10.1038/nrc3820.CrossRefPubMed

15.

Haber, D. A., & Velculescu, V. E. (2014). Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discovery, 4(6), 650–661. doi:10.1158/2159-8290.CD-13-1014.CrossRefPubMedPubMedCentral

16.

Krebs, M. G., Metcalf, R. L., Carter, L., Brady, G., Blackhall, F. H., & Dive, C. (2014). Molecular analysis of circulating tumour cells-biology and biomarkers. Nature Reviews. Clinical Oncology, 11(3), 129–144. doi:10.1038/nrclinonc.2013.253.CrossRefPubMed

17.

Lianidou, E. S., Mavroudis, D., & Georgoulias, V. (2013). Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. British Journal of Cancer, 108(12), 2426–2432. doi:10.1038/bjc.2013.265.CrossRefPubMedPubMedCentral

18.

Klein, C. A. (2009). Parallel progression of primary tumours and metastases. Nature Reviews Cancer, 9(4), 302–312. doi:10.1038/nrc2627.CrossRefPubMed

19.

Grade, M., Becker, H., Liersch, T., Ried, T., & Ghadimi, B. M. (2006). Molecular cytogenetics: genomic imbalances in colorectal cancer and their clinical impact. Cellular Oncology The Official Journal of the International Society for Cellular Oncology, 28(3), 71–84.PubMedPubMedCentral

20.

Bruin, S. C., Klijn, C., Liefers, G. J., Braaf, L. M., Joosse, S. A., van Beers, E. H., et al. (2010). Specific genomic aberrations in primary colorectal cancer are associated with liver metastases. BMC Cancer, 10, 662. doi:10.1186/1471-2407-10-662.CrossRefPubMedPubMedCentral

21.

Pantel, K., Deneve, E., Nocca, D., Coffy, A., Vendrell, J. P., Maudelonde, T., et al. (2012). Circulating epithelial cells in patients with benign colon diseases. Clinical Chemistry, 58(5), 936–940. doi:10.1373/clinchem.2011.175570.CrossRefPubMed

22.

Pantel, K., & Brakenhoff, R. H. (2004). Dissecting the metastatic cascade. Nature Reviews Cancer, 4(6), 448–456. doi:10.1038/nrc1370.CrossRefPubMed

23.

Weigelt, B., Glas, A. M., Wessels, L. F., Witteveen, A. T., Peterse, J. L., & Veer, L. J. (2003). Gene expression profiles of primary breast tumors maintained in distant metastases. Proceedings of the National Academy of Sciences of the United States of America, 100(26), 15901–15905. doi:10.1073/pnas.2634067100.CrossRefPubMedPubMedCentral

24.

Weigelt, B., Hu, Z., He, X., Livasy, C., Carey, L. A., Ewend, M. G., et al. (2005). Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Research, 65(20), 9155–9158. doi:10.1158/0008-5472.CAN-05-2553.CrossRefPubMed

25.

Shah, S. P., Morin, R. D., Khattra, J., Prentice, L., Pugh, T., Burleigh, A., et al. (2009). Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature, 461(7265), 809–813. doi:10.1038/nature08489.CrossRefPubMed

26.

Schmidt-Kittler, O., Ragg, T., Daskalakis, A., Granzow, M., Ahr, A., Blankenstein, T. J., et al. (2003). From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 100(13), 7737–7742. doi:10.1073/pnas.1331931100.CrossRefPubMedPubMedCentral

27.

Weckermann, D., Polzer, B., Ragg, T., Blana, A., Schlimok, G., Arnholdt, H., et al. (2009). Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, 27(10), 1549–1556. doi:10.1200/JCO.2008.17.0563.CrossRefPubMed

28.

Husemann, Y., Geigl, J. B., Schubert, F., Musiani, P., Meyer, M., Burghart, E., et al. (2008). Systemic spread is an early step in breast cancer. Cancer Cell, 13(1), 58–68. doi:10.1016/j.ccr.2007.12.003.CrossRefPubMed

29.

Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, F., et al. (2012). EMT and dissemination precede pancreatic tumor formation. Cell, 148(1–2), 349–361. doi:10.1016/j.cell.2011.11.025.CrossRefPubMedPubMedCentral

30.

Kang, Y., & Pantel, K. (2013). Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell, 23(5), 573–581. doi:10.1016/j.ccr.2013.04.017.CrossRefPubMedPubMedCentral

31.

Stoecklein, N. H., & Klein, C. A. (2010). Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. International Journal of Cancer/Journal International du cancer, 126(3), 589–598. doi:10.1002/ijc.24916.CrossRefPubMed

32.

Horlings, H. M., Lai, C., Nuyten, D. S., Halfwerk, H., Kristel, P., van Beers, E., et al. (2010). Integration of DNA copy number alterations and prognostic gene expression signatures in breast cancer patients. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 16(2), 651–663. doi:10.1158/1078-0432.CCR-09-0709.CrossRefPubMed

33.

Joosse, S. A. (2012). BRCA1 and BRCA2: a common pathway of genome protection but different breast cancer subtypes. Nature Reviews Cancer, 12(5), 372. doi:10.1038/nrc3181-c2. author reply.CrossRefPubMed

34.

Joosse, S. A., Brandwijk, K. I., Mulder, L., Wesseling, J., Hannemann, J., & Nederlof, P. M. (2011). Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors. Genes, Chromosomes & Cancer, 50(2), 71–81. doi:10.1002/gcc.20833.CrossRef

35.

Lim, E., Vaillant, F., Wu, D., Forrest, N. C., Pal, B., Hart, A. H., et al. (2009). Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nature Medicine, 15(8), 907–913. doi:10.1038/nm.2000.CrossRefPubMed

36.

Molyneux, G., Geyer, F. C., Magnay, F. A., McCarthy, A., Kendrick, H., Natrajan, R., et al. (2010). BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell, 7(3), 403–417. doi:10.1016/j.stem.2010.07.010.CrossRefPubMed

37.

Zahl, P. H., Maehlen, J., & Welch, H. G. (2008). The natural history of invasive breast cancers detected by screening mammography. Archives of Internal Medicine, 168(21), 2311–2316. doi:10.1001/archinte.168.21.2311.CrossRefPubMed

38.

Stella, G. M., Senetta, R., Cassenti, A., Ronco, M., & Cassoni, P. (2012). Cancers of unknown primary origin: current perspectives and future therapeutic strategies. Journal of Translational Medicine, 10, 12. doi:10.1186/1479-5876-10-12.CrossRefPubMedPubMedCentral

39.

Suzuki, M., Mose, E. S., Montel, V., & Tarin, D. (2006). Dormant cancer cells retrieved from metastasis-free organs regain tumorigenic and metastatic potency. The American Journal of Pathology, 169(2), 673–681. doi:10.2353/ajpath.2006.060053.CrossRefPubMedPubMedCentral

40.

Tarin, D. (2012). Clinical and biological implications of the tumor microenvironment. Cancer Microenvironment, 5(2),95–112. doi: 10.1007/s12307-012-0099-6.

41.

Pantel, K., Schlimok, G., Braun, S., Kutter, D., Lindemann, F., Schaller, G., et al. (1993). Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. Journal of the National Cancer Institute, 85(17), 1419–1424.CrossRefPubMed

42.

Janni, W., Vogl, F. D., Wiedswang, G., Synnestvedt, M., Fehm, T., Juckstock, J., et al. (2011). Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse—a European pooled analysis. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 17(9), 2967–2976. doi:10.1158/1078-0432.CCR-10-2515.CrossRefPubMed

43.

Paget, S. (1989). The distribution of secondary growths in cancer of the breast, 1889. Cancer Metastasis Reviews, 8(2), 98–101.PubMed

44.

Yumoto, K., Eber, M. R., Berry, J. E., Taichman, R. S., & Shiozawa, Y. (2014). Molecular pathways: niches in metastatic dormancy. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 20(13), 3384–3389. doi:10.1158/1078-0432.CCR-13-0897.CrossRefPubMedPubMedCentral

45.

Braun, S., Kentenich, C., Janni, W., Hepp, F., de Waal, J., Willgeroth, F., et al. (2000). Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, 18(1), 80–86.PubMed

46.

Braun, S., Vogl, F. D., Naume, B., Janni, W., Osborne, M. P., Coombes, R. C., et al. (2005). A pooled analysis of bone marrow micrometastasis in breast cancer. The New England Journal of Medicine, 353(8), 793–802. doi:10.1056/NEJMoa050434.CrossRefPubMed

47.

Sanger, N., Effenberger, K. E., Riethdorf, S., Van Haasteren, V., Gauwerky, J., Wiegratz, I., et al. (2011). Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. International Journal of Cancer/Journal International du cancer, 129(10), 2522–2526. doi:10.1002/ijc.25895.CrossRefPubMed

48.

Solakoglu, O., Maierhofer, C., Lahr, G., Breit, E., Scheunemann, P., Heumos, I., et al. (2002). Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proceedings of the National Academy of Sciences of the United States of America, 99(4), 2246–2251. doi:10.1073/pnas.042372199.CrossRefPubMedPubMedCentral

49.

Meng, S., Tripathy, D., Frenkel, E. P., Shete, S., Naftalis, E. Z., Huth, J. F., et al. (2004). Circulating tumor cells in patients with breast cancer dormancy. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 10(24), 8152–8162. doi:10.1158/1078-0432.CCR-04-1110.CrossRefPubMed

50.

Tabassum, D. P., & Polyak, K. (2015). Tumorigenesis: it takes a village. Nature Reviews Cancer, 15(8), 473–483. doi:10.1038/nrc3971.CrossRefPubMed

51.

Navin, N. E., & Hicks, J. (2010). Tracing the tumor lineage. Molecular Oncology, 4(3), 267–283. doi:10.1016/j.molonc.2010.04.010.CrossRefPubMedPubMedCentral

52.

Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., et al. (2011). Tumour evolution inferred by single-cell sequencing. Nature, 472(7341), 90–94. doi:10.1038/nature09807.CrossRefPubMedPubMedCentral

53.

De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., et al. (2010). Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. The Lancet Oncology, 11(8), 753–762. doi:10.1016/S1470-2045(10)70130-3.CrossRefPubMed

54.

Hannemann, J., Meyer-Staeckling, S., Kemming, D., Alpers, I., Joosse, S. A., Pospisil, H., et al. (2011). Quantitative high-resolution genomic analysis of single cancer cells. PLoS ONE, 6(11), e26362. doi:10.1371/journal.pone.0026362.CrossRefPubMedPubMedCentral

55.

Gasch, C., Bauernhofer, T., Pichler, M., Langer-Freitag, S., Reeh, M., Seifert, A. M., et al. (2013). Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clinical Chemsistry, 59(1), 252–260. doi:10.1373/clinchem.2012.188557.CrossRef

56.

Maley, C. C., Galipeau, P. C., Finley, J. C., Wongsurawat, V. J., Li, X., Sanchez, C. A., et al. (2006). Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nature Genetics, 38(4), 468–473. doi:10.1038/ng1768.CrossRefPubMed

57.

Notta, F., Mullighan, C. G., Wang, J. C., Poeppl, A., Doulatov, S., Phillips, L. A., et al. (2011). Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature, 469(7330), 362–367. doi:10.1038/nature09733.CrossRefPubMed

58.

Almendro, V., Cheng, Y. K., Randles, A., Itzkovitz, S., Marusyk, A., Ametller, E., et al. (2014). Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Reports, 6(3), 514–527. doi:10.1016/j.celrep.2013.12.041.CrossRefPubMedPubMedCentral

59.

Marusyk, A., Tabassum, D. P., Altrock, P. M., Almendro, V., Michor, F., & Polyak, K. (2014). Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature, 514(7520), 54–58. doi:10.1038/nature13556.CrossRefPubMedPubMedCentral

60.

Calbo, J., van Montfort, E., Proost, N., van Drunen, E., Beverloo, H. B., Meuwissen, R., et al. (2011). A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell, 19(2), 244–256. doi:10.1016/j.ccr.2010.12.021.CrossRefPubMed

61.

Cayrefourcq, L., Mazard, T., Joosse, S., Solassol, J., Ramos, J., Assenat, E., et al. (2015). Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Research, 75(5), 892–901. doi:10.1158/0008-5472.CAN-14-2613.CrossRefPubMed

62.

Aceto, N., Bardia, A., Miyamoto, D. T., Donaldson, M. C., Wittner, B. S., Spencer, J. A., et al. (2014). Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell, 158(5), 1110–1122. doi:10.1016/j.cell.2014.07.013.CrossRefPubMedPubMedCentral

63.

Kreso, A., O’Brien, C. A., van Galen, P., Gan, O. I., Notta, F., Brown, A. M., et al. (2013). Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science, 339(6119), 543–548. doi:10.1126/science.1227670.CrossRefPubMed

64.

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., et al. (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Medicine, 2(3), e73. doi:10.1371/journal.pmed.0020073.CrossRefPubMedPubMedCentral

65.

Heitzer, E., Auer, M., Gasch, C., Pichler, M., Ulz, P., Hoffmann, E. M., et al. (2013). Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Research, 73(10), 2965–2975. doi:10.1158/0008-5472.CAN-12-4140.CrossRefPubMed

66.

Wu, C. C., Maher, M. M., & Shepard, J. A. (2011). Complications of CT-guided percutaneous needle biopsy of the chest: prevention and management. AJR. American Journal of Roentgenology, 196(6), W678–W682. doi:10.2214/AJR.10.4659.CrossRefPubMed

67.

Bednarz-Knoll, N., Alix-Panabieres, C., & Pantel, K. (2012). Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Reviews, 31(3–4), 673–687. doi:10.1007/s10555-012-9370-z.CrossRefPubMed

68.

Yu, M., Bardia, A., Wittner, B. S., Stott, S. L., Smas, M. E., Ting, D. T., et al. (2013). Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science, 339(6119), 580–584. doi:10.1126/science.1228522.CrossRefPubMedPubMedCentral

69.

Guzvic, M., Braun, B., Ganzer, R., Burger, M., Nerlich, M., Winkler, S., et al. (2014). Combined genome and transcriptome analysis of single disseminated cancer cells from bone marrow of prostate cancer patients reveals unexpected transcriptomes. Cancer Research, 74(24), 7383–7394. doi:10.1158/0008-5472.CAN-14-0934.CrossRefPubMed

70.

Miyamoto, D. T., Zheng, Y., Wittner, B. S., Lee, R. J., Zhu, H., Broderick, K. T., et al. (2015). RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science, 349(6254), 1351–1356. doi:10.1126/science.aab0917.CrossRefPubMed

71.

Miyamoto, D. T., Lee, R. J., Stott, S. L., Ting, D. T., Wittner, B. S., Ulman, M., et al. (2012). Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discovery, 2(11), 995–1003. doi:10.1158/2159-8290.CD-12-0222.CrossRefPubMedPubMedCentral

72.

Almendro, V., Kim, H. J., Cheng, Y. K., Gonen, M., Itzkovitz, S., Argani, P., et al. (2014). Genetic and phenotypic diversity in breast tumor metastases. Cancer Research, 74(5), 1338–1348. doi:10.1158/0008-5472.CAN-13-2357-T.CrossRefPubMedPubMedCentral

Title: Genetic traits for hematogeneous tumor cell dissemination in cancer patients
Authors: Simon A. Joosse
Klaus Pantel
Publication date: 01-03-2016
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 1/2016
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-016-9611-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2016

Molecular evolution of colorectal cancer: from multistep carcinogenesis to the big bang

Biography—József Tímár

Genetic evolution during tumor progression: from basic research to clinical practice

Catalog of genetic progression of human cancers: breast cancer

Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice

Progression and metastasis of lung cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer